Editas' sickle cell CRISPR therapy shows early promise, but can it stand out against Vertex? (www.fiercebiotech.com)

submitted 1 year ago by mem_somerville_kbin@kbin.social to c/science@kbin.social

0 comments fedilink hide all child comments

Editas Medicine has shared early clinical data on the cell therapy it is developing to challenge Vertex and CRISPR Therapeutics for the sickle cell market. The CRISPR-edited therapy showed clear signs of efficacy but, with its rivals awaiting FDA approval, differentiating a late-to-market challenger could be tough.

no comments (yet)

sorted by: hot top controversial new old

there doesn't seem to be anything here

this post was submitted on 17 Jun 2023

7 points (100.0% liked)

Science

76 readers

7 users here now

This magazine is dedicated to discussions on scientific discoveries, research, and theories across various fields, including physics, chemistry, biology, astronomy, and more. Whether you are a scientist, a science enthusiast, or simply curious about the world around us, this is the place for you. Here you can share your knowledge, ask questions, and engage in discussions on a wide range of scientific topics. From the latest breakthroughs to historical discoveries and ongoing research, this category covers a wide range of topics related to science.

founded 1 year ago